Last updated: October 25, 2026

Application No. 17/266,592

Homologous Recombination Reporter Construct and Uses Thereof

Final Rejection

Filed

Feb 06, 2021

Priority

Aug 06, 2018 — provisional 62/715,117 +2 more

Examiner

SMALL, KATHERINE R

Art Unit

1633

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Nemametrix Inc.

OA Round

4 (Final)

Interview Optional

— +29.6% interview lift. Examiner has a relatively high allowance rate (69%); +29.6% interview lift. A written response may suffice.

Based on 62 resolved cases, 2023–2026

Examiner Intelligence

SMALL, KATHERINE R View full profile →

Grants 69% — above average

Career Allowance Rate

43 granted / 62 resolved

+9.4% vs TC avg

Strong +30% interview lift

Without

With

+29.6%

Interview Lift

resolved cases with interview

Typical timeline

3y 10m

Avg Prosecution

21 currently pending

Career history

Total Applications

across all art units

Statute-Specific Performance

§101

5.1%

-34.9% vs TC avg

§103

41.6%

+1.6% vs TC avg

§102

24.0%

-16.0% vs TC avg

§112

27.4%

-12.6% vs TC avg

Black line = Tech Center average estimate • Based on career data from 62 resolved cases

Prosecution Timeline

Show 3 earlier events

Jul 19, 2024

Final Rejection mailed

Sep 13, 2024

Interview Requested

Jan 20, 2025

Notice of Allowance

Aug 20, 2025

Request for Continued Examination

Aug 22, 2025

Response after Non-Final Action

Jan 22, 2026

Non-Final Rejection mailed

Mar 12, 2026

Response Filed

Apr 29, 2026

Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

17/288,504

Patent 12760287

CONSTRUCTS FOR IMPROVED HDR-DEPENDENT GENOMIC EDITING

5y 5m to grant Granted Oct 13, 2026

17/283,598

Patent 12729384

A METHOD TO TREAT DISEASE USING A NUCLEIC ACID VECTOR ENCODING A HIGHLY COMPACT MULTI-INPUT LOGIC GATE

5y 5m to grant Granted Sep 08, 2026

17/438,833

Patent 12714727

PHARMACEUTICAL COMPOSITION FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS

4y 11m to grant Granted Aug 25, 2026

17/440,350

Patent 12642256

HEMOPHILIA B RAT MODEL

4y 8m to grant Granted Jun 02, 2026

17/284,043

Patent 12630821

Selective Curbing of Unwanted RNA Editing (SECURE) DNA Base Editor Variants

5y 1m to grant Granted May 19, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6

Expected OA Rounds

69%

Grant Probability

99%

With Interview (+29.6%)

3y 10m (~0m remaining)

Median Time to Grant

High

PTA Risk

Based on 62 resolved cases by this examiner. Grant probability derived from career allowance rate.